Skip Navigation


European Heart Journal Advance Access originally published online on June 20, 2008
European Heart Journal 2008 29(15):1798-1799; doi:10.1093/eurheartj/ehn274
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
29/15/1798    most recent
ehn274v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Israel, C. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Israel, C. W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Effect of statins in ‘upstream therapy’ of atrial fibrillation: better reliability with implantable cardiac monitors

Carsten W. Israel*

J. W. Goethe University Hospital, Department of Medicine, Division of Cardiology, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany

* Corresponding author. Tel: +49 69 6301 7387, Fax: +49 69 6301 3813, Email: C.W.Israel@em.uni-frankfurt.de

This editorial refers to ‘Beneficial effects of statin therapy for prevention of atrial fibrillation following DDDR pacemaker implantation’{dagger} by A.M. Gillis et al., on page 1873

Footnotes

The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.

The first 10% of the full text of this article appears below.

The therapeutic potential to suppress atrial fibrillation (AF) is currently under evaluation for several non-antiarrhythmic drugs: angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, aldosterone receptor antagonists, anti-inflammatory and antioxidative drugs, polyunsaturated fatty acids, and HMG-CoA reductase inhibitors, i.e. statins.

Statins have shown multiple (‘pleiotropic’) beneficial effects beyond lowering of cholesterol: anti-inflammatory, antioxidant, and antifibrotic effects, modulation of matrix metalloproteinases, interaction with peroxisome receptors that regulate proliferation, and with endothelial nitric oxide synthase, protecting atrial myocardium during . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Beneficial effects of statin therapy for prevention of atrial fibrillation following DDDR pacemaker implantation
Anne M. Gillis, Margaret Morck, Derek V. Exner, Andrea Soo, M. Sarah Rose, Robert S. Sheldon, Henry J. Duff, Katherine M. Kavanagh, L. Brent Mitchell, and D. George Wyse
EHJ 2008 29: 1873-1880. [Abstract] [FREE Full Text]